Term ends Sep 7, 2027 · High confidence
20-year base term ended Oct 26, 2026
Held by Impact Biomedicines, Inc.
Filed Oct 14, 2008 as application 12/251,061 · Granted Mar 13, 2012
Base term plus 316 days of patent term adjustment (USPTO delay)
Today
2006
2027
Clock starts
Oct 26, 2006
Oct 26, 2006
Term ends
Sep 7, 2027
Sep 7, 2027
Granted
Mar 13, 2012
Mar 13, 2012
base term
patent term adjustment
fee events
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
316
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
5
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 316 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Oct 26, 2006, when application 11/588,638, the earliest non-provisional in its chain, was filed (this one was filed Oct 14, 2008) | Oct 26, 2026 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +316 days, USPTO patent term adjustment record | Sep 7, 2027 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 7, 2027 | High confidence |
This family
| US 7,528,143 | In force no later than Nov 2031 | no later than Nov 2031 |
| US 7,825,246 | In force no later than Mar 2027 | no later than Mar 2027 |
| US 8,133,900 | this patent Sep 2027 | Sep 2027 |
| US 8,138,199 | In force Jun 2028 | Jun 2028 |
| US 8,604,042 | Term ended Oct 2026 | Oct 2026 |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Dec 18, 2008 Reel 22001, frame 901 | Hood, John D.; Noronha, Glenn | Targegen, Inc. | Assignment of Assignor's Interest |
| Oct 18, 2010 Reel 25155, frame 89 | Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M. | Targegen, Inc. | Assignment of Assignor's Interest |
| Jan 6, 2014 Reel 31923, frame 634 | Noronha, Glenn; Mak, Chi Ching; Cao, Jianguo; Renick, Joel; McPherson, Andrew; Zeng, Binqi; Pathak, Ved P.; Lohse, Daniel L.; Hood, John D.; Soll, Richard M. | Targegen, Inc. | Corrective Assignment to Correct the State of Incorporation from a California Corporation to a Delaware Corporation for the Assignment Previously Recorded on Reel 025155 Frame 0089. Assignor(S) Hereby Confirms the State of Incorporation for Targegen, Inc. to Be a Delaware Corporation. |
| May 25, 2017 Reel 42586, frame 643 | Impact Therapeutics, Inc. | Impact Biomedicines, Inc. | Change of Name |
| May 25, 2017 Reel 42512, frame 179 | Targegen, Inc. | Impact Therapeutics, Inc. | Assignment of Assignor's Interest |
| Nov 30, 2017 Reel 44572, frame 660 | Impact Biomedicines, Inc. | Lind S.A., LLC, as Collateral Agent | Security Interest |
| Feb 12, 2018 Reel 44904, frame 628 | Lind S.A. LLC, as Collateral Agent | Impact Biomedicines, Inc. | Release of Security Interest |
| Aug 21, 2019 Reel 50297, frame 562 | Targegen, Inc. | Impact Biomedicines, Inc. | Corrective Assignment to Correct the Assignee's Name Previously Recorded at Reel: 042512 Frame: 0179. Assignor(S) Hereby Confirms the Assignment . |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2027
Term ends Sep 7, 2027. No further fees fall due before then
Note
The 316 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
104
later US patents cite this one
That is top 10% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.